DAM
ALXN

Deltec Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Deltec Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,000
Closed -$478K – 202
2017
Q4 		$478K Buy
+4,000
New +$487K 0.1% 126
2016
Q4 		– Sell
-12,200
Closed -$1.5M – 192
2016
Q3 		$1.5M Buy
+12,200
New +$1.57M 0.34% 69

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Deltec Asset Management's ALXN Position: Q1 2018 in Review

Deltec Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 4,000 shares — an estimated $478K sold.

Deltec Asset Management first reported a position in ALXN in Q3 2016 and held it in 2 quarters. The position peaked at $1.5M in Q3 2016. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Deltec Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Deltec Asset Management sold 4,000 Alexion Pharmaceuticals shares in Q1 2018, an estimated $478K.
  • Deltec Asset Management first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Deltec Asset Management's Alexion Pharmaceuticals position peaked at $1.5M in Q3 2016.
  • 596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Deltec Asset Management's 13F filing for Q1 2018, filed 11 May 2018.